Skip to content
HCC Buddy home

C92.A0 ICD-10-CM Code: Acute myeloid leukemia with multilineage dysplasia, not having achieved remission

C92.A0 maps to CMS-HCC V28 17. A source-labeled RAF reference is available. Confirm the documented diagnosis and applicable coding requirements. MEAT criteria · RAF Calculator · HCC Buddy coding tools

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupC92.A0

FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)

C92.A0

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Acute myeloid leukemia with multilineage dysplasia, not having achieved remission

A type of acute myeloid leukemia where multiple cell lines show abnormal development and the cancer has not responded adequately to initial treatment.

Buddy the Bee presenting code insight

Buddy Insight

Acute myeloid leukemia with multilineage dysplasia (AML-MLD) is an AML subtype characterized by dysplastic changes in two or more myeloid cell lines (erythroid, granulocytic, megakaryocytic), often arising from prior myelodysplastic syndrome (MDS).

OverviewRisk ModelsCode BookDocumentationAuditNotesEdition comparison

CMS-HCC V28

HCC 17

Coefficient HCC 17: 4.209 (Community Non-Dual Aged (CNA))

CMS-HCC V24

Historical

Historical

Not used for CY2026 payment

ACA/HHS

HCC 008

Code-level coefficient reference

ESRD/PACE

HCC 8

Code-level coefficient reference

RXHCC

HCC 19

Code-level coefficient reference

Code Book Path

Official
C92Myeloid leukemiaC92.AAcute myeloid leukemia with multilineage dysplasiaC92.A0Acute myeloid leukemia with multilineage dysplasia, not having achieved remission

Inclusion Terms

Official
  • Acute myeloid leukemia with multilineage dysplasia with failed remission
  • Acute myeloid leukemia with multilineage dysplasia NOS
  • Acute myeloid leukemia with dysplasia of remaining hematopoesis and/or myelodysplastic disease in its historyInherited from C92.A

Excludes 2

Official
  • Kaposi's sarcoma of lymph nodes (C46.3)Inherited from C81-C96
  • secondary and unspecified neoplasm of lymph nodes (C77.-)Inherited from C81-C96
  • secondary neoplasm of bone marrow (C79.52)Inherited from C81-C96
  • secondary neoplasm of spleen (C78.89)Inherited from C81-C96

Related Codes

Official
C92.A1Acute myeloid leukemia with multilineage dysplasia, in remissionC92.A2Acute myeloid leukemia with multilineage dysplasia, in relapse

Includes

Official
  • granulocytic leukemiaInherited from C92
  • myelogenous leukemiaInherited from C92

Excludes 1

Official
  • personal history of leukemia (Z85.6)Inherited from C92

Code First

Official

No Code First sequencing instructions are included in this display for C92.A0. Check the code and parent instructions in the Code Book.

Use Additional

Official

No Use Additional Code instructions are included in this display for C92.A0. Check the code and parent instructions in the Code Book.

Code Also

Official
  • , if applicable, pancytopenia (acquired) (D61.818)Inherited from C92

Buddy Documentation Tip

HCC Buddy guidance
Documentation must confirm the presence of multilineage dysplasia (dysplasia in 50% or more of cells in at least two myeloid lineages) on bone marrow examination.
Prior history of MDS should be documented if present, as this supports the diagnosis.
Cytogenetic and molecular testing results, blast percentage, and MDS-related changes should be recorded.
Treatment response and current disease status must be explicitly stated.

MEAT Support

HCC Buddy guidance
Documentation must confirm the presence of multilineage dysplasia (dysplasia in 50% or more of cells in at least two myeloid lineages) on bone marrow examination.
Prior history of MDS should be documented if present, as this supports the diagnosis.
Cytogenetic and molecular testing results, blast percentage, and MDS-related changes should be recorded.
Treatment response and current disease status must be explicitly stated.

Audit Caution

HCC Buddy guidance
The threshold for AML vs. MDS remains 20% blasts -
do not code AML-MLD for MDS with excess blasts below this threshold. Multilineage dysplasia must be morphologically confirmed, not assumed from clinical history. Some patients with de novo AML may have dysplasia that does not constitute the AML-MLD category per WHO classification. Prior therapy-related changes may mimic multilineage dysplasia.

Common Mistakes

HCC Buddy guidance
C92.00 (acute myeloblastic leukemia, not in remission) is for AML without significant multilineage dysplasia.
D46 codes (myelodysplastic syndromes) are for MDS that has not yet transformed to AML (less than 20% blasts).
C92.50 (acute myelomonocytic leukemia) has monocytic differentiation.
C92.90 (myeloid leukemia, unspecified) is less specific and should not be used when AML-MLD is confirmed.

Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →

Is C92.A0 an HCC code?

Yes. C92.A0 (Acute myeloid leukemia with multilineage dysplasia, not having achieved remission) maps to HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 4.209. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.

Coder answer: C92.A0 is billable and maps to V28 HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.

Code
C92.A0
Description
Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
HCC (V28)
HCC 17 — Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic
RAF reference coefficient
4.209
Billable
Yes
Payment year
2026

HCC Category Mapping

V28HCC 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic
4.209
ESRDHCC 8, Metastatic Cancer and Acute Leukemia
Not separately weighted
RxHCCHCC 19, Leukemias and Other Hematologic Cancers
Not separately weighted

These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.

Work C92.A0 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →

MEAT review for C92.A0

For C92.A0, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.

  • MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
  • EEvaluate: test results, medication response, or physical findings reviewed by the provider
  • AAssess: explicit mention in the assessment or plan with acknowledgment of status
  • TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Coder workflow notes

Get the V28 mapping + MEAT cheat sheet

One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.

Free PDF. No card. Unsubscribe anytime.

What This Code Means

C92.A0 is the ICD-10-CM diagnosis code for acute myeloid leukemia with multilineage dysplasia, not having achieved remission. A type of acute myeloid leukemia where multiple cell lines show abnormal development and the cancer has not responded adequately to initial treatment. C92.A0 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).

Under the CMS-HCC V28 risk adjustment model, C92.A0 maps to Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic (HCC 17) with a source-labeled community, non-dual, aged reference coefficient of 4.209. For CY2026 non-PACE Medicare Advantage, CMS uses 100% of the 2024 CMS-HCC model (V28). PACE uses a separate model blend. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.

Multilineage dysplasia is a morphologic finding that should be documented in the pathology report. For C92.A0, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for C92.A0 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

  • •Multilineage dysplasia is a morphologic finding that should be documented in the pathology report
  • •Confirm this is not a myelodysplastic syndrome but rather acute myeloid leukemia with dysplastic features

Clinical Significance

Acute myeloid leukemia with multilineage dysplasia (AML-MLD) is an AML subtype characterized by dysplastic changes in two or more myeloid cell lines (erythroid, granulocytic, megakaryocytic), often arising from prior myelodysplastic syndrome (MDS). AML-MLD typically occurs in older adults and carries an adverse prognosis compared to de novo AML without dysplasia. The 'not in remission' status indicates active disease requiring treatment.

Documentation Requirements

  • ✓Documentation must confirm the presence of multilineage dysplasia (dysplasia in 50% or more of cells in at least two myeloid lineages) on bone marrow examination.
  • ✓Prior history of MDS should be documented if present, as this supports the diagnosis.
  • ✓Cytogenetic and molecular testing results, blast percentage, and MDS-related changes should be recorded.
  • ✓Treatment response and current disease status must be explicitly stated.

Commonly Confused Codes

  • •C92.00 (acute myeloblastic leukemia, not in remission) is for AML without significant multilineage dysplasia.
  • •D46 codes (myelodysplastic syndromes) are for MDS that has not yet transformed to AML (less than 20% blasts).
  • •C92.50 (acute myelomonocytic leukemia) has monocytic differentiation.
  • •C92.90 (myeloid leukemia, unspecified) is less specific and should not be used when AML-MLD is confirmed.

Child Codes

C92.A0Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
HCC 17
C92.A1Acute myeloid leukemia with multilineage dysplasia, in remission
HCC 17
C92.A2Acute myeloid leukemia with multilineage dysplasia, in relapse
HCC 17

Code Hierarchy

└C92Myeloid leukemia└C92.AAcute myeloid leukemia with multilineage dysplasia└C92.A0Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
└C92.A0Acute myeloid leukemia with multilineage dysplasia, not having achieved remission

Also searched as

  • C92 A0
  • C92A0

For C92.A0, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.

C92.A0 maps to CMS-HCC V28 category 17, Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic. See the ICD-10 to HCC mapping hub for how the V28 crosswalk works. The mapping identifies a payment HCC category for C92.A0. Review its source-labeled HCC coefficient above, check the RAF Calculator with complete member context for CMS-HCC V28 PY2026, and confirm the documentation the chart needs before the code is submitted. HCC Buddy shows no RAF score unless every required source and calculation check passes.

More on C92.A0

Code family

Every C92 code with its CMS-HCC V28 statusMyeloid leukemia, 30 billable codes

Work C92.A0 in HCC Buddy

Open C92.A0 in the Code Book for the full Index-to-Tabular path, MEAT checklist, and V28 HCC mapping, or in the Encoder to code from a keyword search. Pro includes 7 days to try everything, no card required.

Open in Code BookOpen in EncoderStart Pro